CRISPR Therapeutics Improves Cash Position Amid Pipeline Expansion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy CRSP?
Source: Fool
- Cash Position: As of the end of 2025, CRISPR Therapeutics holds nearly $2 billion in cash and cash equivalents, providing substantial financial support for ramping up sales of its only approved gene-editing therapy, Casgevy, thereby enhancing its competitive position in the market.
- Casgevy Sales Growth: Priced at $2.2 million per treatment, Casgevy generated $116 million in sales for 2025, including $54 million in the fourth quarter alone, indicating an accelerating sales trend, despite the company reporting a loss of $578.6 million last year.
- Clinical Trial Pipeline: CRISPR has five other therapies in clinical trials, with CXT310 and CXT320 targeting cardiovascular diseases, and CTX112 for various cancers and autoimmune disorders, showcasing the company's potential in larger markets.
- Gene Editing Prospects: CRISPR's gene-editing technology not only treats diseases but may also cure patients; although the high cost of Casgevy limits its patient population, the company's strong cash flow provides the necessary time to navigate future therapy approvals.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRSP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRSP
Wall Street analysts forecast CRSP stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 56.860
Low
50.00
Averages
78.89
High
105.00
Current: 56.860
Low
50.00
Averages
78.89
High
105.00
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CRISPR Therapeutics Improves Cash Position Amid Pipeline Expansion
- Cash Position: As of the end of 2025, CRISPR Therapeutics holds nearly $2 billion in cash and cash equivalents, providing substantial financial support for ramping up sales of its only approved gene-editing therapy, Casgevy, thereby enhancing its competitive position in the market.
- Casgevy Sales Growth: Priced at $2.2 million per treatment, Casgevy generated $116 million in sales for 2025, including $54 million in the fourth quarter alone, indicating an accelerating sales trend, despite the company reporting a loss of $578.6 million last year.
- Clinical Trial Pipeline: CRISPR has five other therapies in clinical trials, with CXT310 and CXT320 targeting cardiovascular diseases, and CTX112 for various cancers and autoimmune disorders, showcasing the company's potential in larger markets.
- Gene Editing Prospects: CRISPR's gene-editing technology not only treats diseases but may also cure patients; although the high cost of Casgevy limits its patient population, the company's strong cash flow provides the necessary time to navigate future therapy approvals.
See More
Gene Drive Technology as a Solution to Invasive Species
- Global Economic Impact: According to Ben Lamm, CEO of Colossal Biosciences, invasive species result in a staggering $5.4 trillion in global economic losses, with the U.S. alone suffering over $500 billion annually, highlighting the urgent need for effective control methods.
- Humane Solution: Colossal's gene drive technology proposes using genetically modified invasive animals that produce only male offspring, eliminating the need for mass culling and poison, showcasing a more humane approach that also offers reversibility, a feature lacking in traditional methods.
- Market Potential: Companies like CRISPR Therapeutics, Beam Therapeutics, and Intellia Therapeutics are positioning their genome editing platforms as foundational infrastructure for gene drive applications, which could significantly expand their market potential beyond rare disease therapeutics if regulatory acceptance is achieved.
- Commercial Opportunity: Lamm noted that Texas has declared the screwworm a national emergency, indicating a substantial commercial opportunity in invasive species control that could yield billions for related companies, especially if gene drive technology becomes the standard.
See More
CRISPR Therapeutics: Potential Breakthroughs in Gene Editing
- Pipeline Potential: CRISPR Therapeutics, valued at nearly $5 billion, has underperformed over the past five years; however, its pipeline candidates like CTX310 targeting cardiovascular disease could redefine treatment paradigms by addressing high-risk patients' unmet needs.
- Therapeutic Innovation: CTX310 aims to inhibit the ANGPTL3 gene, potentially offering a one-time gene-editing solution for the 40 million Americans with elevated LDL and triglyceride levels, significantly improving patient outcomes and filling existing treatment gaps.
- Additional Pipeline Opportunities: In addition to CTX310, CRISPR is developing CTX320, which targets lipoprotein(a) as a risk factor for major cardiovascular events; if approved, this could represent a significant therapeutic breakthrough, enhancing the company's competitive position in biotech.
- Risks and Rewards: While CRISPR Therapeutics has a promising pipeline, it currently generates little revenue and operates at a loss, with clinical or regulatory setbacks posing substantial risks to its stock price, making it suitable for investors with a higher risk tolerance.
See More
CRISPR Therapeutics Faces Significant Challenges Ahead
- Portfolio Position: CRISPR Therapeutics is currently the second-largest holding in Cathie Wood's Ark Innovation ETF, representing 6.6% of the overall portfolio, highlighting its appeal in the biotech sector despite profitability challenges.
- Profitability Issues: Despite receiving approval for Casgevy in 2023, Vertex Pharmaceuticals failed to generate any profits to share with CRISPR, leading to a staggering loss of $664.6 million for CRISPR last year, undermining investor confidence in future earnings.
- Manufacturing Challenges: The collaboration between CRISPR and Vertex faces severe manufacturing hurdles, with only 5 patients successfully receiving the final product injection of Casgevy in 2024, while competitor Genetix's Lyfgenia therapy achieved over 100 infusions in the same year, illustrating intense market competition.
- New Drug Candidates: CRISPR expects to provide an update on CTX310 in the second half of 2026, which has the potential to generate billions in annual sales, but its long-term safety profile remains uncertain, necessitating cautious risk assessment by investors.
See More
CRISPR Therapeutics Faces Challenges and Opportunities
- Investment Appeal: CRISPR Therapeutics is currently the second-largest holding in Cathie Wood's Ark Innovation ETF at 6.6%, attracting investor interest despite challenges, indicating its potential for high returns.
- Sales Growth Issues: Despite receiving approval in 2023, Casgevy's sales have not generated profits for CRISPR Therapeutics, as Vertex Pharmaceuticals has yet to achieve profitability, raising investor concerns about future earnings.
- Manufacturing Challenges: In 2024, 54 patients underwent stem cell collection, but only 5 received Casgevy infusions, with manufacturing difficulties intensifying competition from Genetix's Lyfgenia therapy, which has shown better patient outcomes.
- Pipeline Progress Anticipation: CRISPR expects to update on CTX310's progress in the second half of 2026, with early trials showing significant lipid-lowering effects, potentially leading to billions in annual sales if successful, though long-term safety remains uncertain.
See More
Cathie Wood Shifts AI Investment Focus to Healthcare
- Portfolio Rebalancing: Cathie Wood's aggressive shift from mega-cap tech and semiconductor stocks to increasing her stake in Tempus AI reflects her strong conviction in AI innovation within healthcare, particularly in disease detection and drug development.
- Market Trend Insight: As AI infrastructure becomes crowded and capital-intensive, ARK Invest's strategic pivot towards application-driven intelligence indicates that healthcare is poised to be the next significant frontier for AI value creation, especially in the transformation of precision medicine.
- Clinical Data Utilization: Tempus AI leverages vast clinical and genomic datasets to drive AI-powered diagnostics and treatment recommendations, and despite its shares declining over 20% year-to-date, ARK's continued buying demonstrates unwavering confidence in its long-term potential.
- Industry Structural Shift: The pharmaceutical sector is expected to face a patent cliff in the next five years, creating opportunities for AI-native platforms to accelerate drug discovery and optimize clinical trials, with emerging players like Totaligent enhancing their biologics-driven data capabilities through strategic acquisitions.
See More
CRISPR Therapeutics Improves Cash Position Amid Pipeline Expansion
- Cash Position: As of the end of 2025, CRISPR Therapeutics holds nearly $2 billion in cash and cash equivalents, providing substantial financial support for ramping up sales of its only approved gene-editing therapy, Casgevy, thereby enhancing its competitive position in the market.
- Casgevy Sales Growth: Priced at $2.2 million per treatment, Casgevy generated $116 million in sales for 2025, including $54 million in the fourth quarter alone, indicating an accelerating sales trend, despite the company reporting a loss of $578.6 million last year.
- Clinical Trial Pipeline: CRISPR has five other therapies in clinical trials, with CXT310 and CXT320 targeting cardiovascular diseases, and CTX112 for various cancers and autoimmune disorders, showcasing the company's potential in larger markets.
- Gene Editing Prospects: CRISPR's gene-editing technology not only treats diseases but may also cure patients; although the high cost of Casgevy limits its patient population, the company's strong cash flow provides the necessary time to navigate future therapy approvals.
See More
Gene Drive Technology as a Solution to Invasive Species
- Global Economic Impact: According to Ben Lamm, CEO of Colossal Biosciences, invasive species result in a staggering $5.4 trillion in global economic losses, with the U.S. alone suffering over $500 billion annually, highlighting the urgent need for effective control methods.
- Humane Solution: Colossal's gene drive technology proposes using genetically modified invasive animals that produce only male offspring, eliminating the need for mass culling and poison, showcasing a more humane approach that also offers reversibility, a feature lacking in traditional methods.
- Market Potential: Companies like CRISPR Therapeutics, Beam Therapeutics, and Intellia Therapeutics are positioning their genome editing platforms as foundational infrastructure for gene drive applications, which could significantly expand their market potential beyond rare disease therapeutics if regulatory acceptance is achieved.
- Commercial Opportunity: Lamm noted that Texas has declared the screwworm a national emergency, indicating a substantial commercial opportunity in invasive species control that could yield billions for related companies, especially if gene drive technology becomes the standard.
See More
CRISPR Therapeutics: Potential Breakthroughs in Gene Editing
- Pipeline Potential: CRISPR Therapeutics, valued at nearly $5 billion, has underperformed over the past five years; however, its pipeline candidates like CTX310 targeting cardiovascular disease could redefine treatment paradigms by addressing high-risk patients' unmet needs.
- Therapeutic Innovation: CTX310 aims to inhibit the ANGPTL3 gene, potentially offering a one-time gene-editing solution for the 40 million Americans with elevated LDL and triglyceride levels, significantly improving patient outcomes and filling existing treatment gaps.
- Additional Pipeline Opportunities: In addition to CTX310, CRISPR is developing CTX320, which targets lipoprotein(a) as a risk factor for major cardiovascular events; if approved, this could represent a significant therapeutic breakthrough, enhancing the company's competitive position in biotech.
- Risks and Rewards: While CRISPR Therapeutics has a promising pipeline, it currently generates little revenue and operates at a loss, with clinical or regulatory setbacks posing substantial risks to its stock price, making it suitable for investors with a higher risk tolerance.
See More
CRISPR Therapeutics Faces Significant Challenges Ahead
- Portfolio Position: CRISPR Therapeutics is currently the second-largest holding in Cathie Wood's Ark Innovation ETF, representing 6.6% of the overall portfolio, highlighting its appeal in the biotech sector despite profitability challenges.
- Profitability Issues: Despite receiving approval for Casgevy in 2023, Vertex Pharmaceuticals failed to generate any profits to share with CRISPR, leading to a staggering loss of $664.6 million for CRISPR last year, undermining investor confidence in future earnings.
- Manufacturing Challenges: The collaboration between CRISPR and Vertex faces severe manufacturing hurdles, with only 5 patients successfully receiving the final product injection of Casgevy in 2024, while competitor Genetix's Lyfgenia therapy achieved over 100 infusions in the same year, illustrating intense market competition.
- New Drug Candidates: CRISPR expects to provide an update on CTX310 in the second half of 2026, which has the potential to generate billions in annual sales, but its long-term safety profile remains uncertain, necessitating cautious risk assessment by investors.
See More
CRISPR Therapeutics Faces Challenges and Opportunities
- Investment Appeal: CRISPR Therapeutics is currently the second-largest holding in Cathie Wood's Ark Innovation ETF at 6.6%, attracting investor interest despite challenges, indicating its potential for high returns.
- Sales Growth Issues: Despite receiving approval in 2023, Casgevy's sales have not generated profits for CRISPR Therapeutics, as Vertex Pharmaceuticals has yet to achieve profitability, raising investor concerns about future earnings.
- Manufacturing Challenges: In 2024, 54 patients underwent stem cell collection, but only 5 received Casgevy infusions, with manufacturing difficulties intensifying competition from Genetix's Lyfgenia therapy, which has shown better patient outcomes.
- Pipeline Progress Anticipation: CRISPR expects to update on CTX310's progress in the second half of 2026, with early trials showing significant lipid-lowering effects, potentially leading to billions in annual sales if successful, though long-term safety remains uncertain.
See More
Cathie Wood Shifts AI Investment Focus to Healthcare
- Portfolio Rebalancing: Cathie Wood's aggressive shift from mega-cap tech and semiconductor stocks to increasing her stake in Tempus AI reflects her strong conviction in AI innovation within healthcare, particularly in disease detection and drug development.
- Market Trend Insight: As AI infrastructure becomes crowded and capital-intensive, ARK Invest's strategic pivot towards application-driven intelligence indicates that healthcare is poised to be the next significant frontier for AI value creation, especially in the transformation of precision medicine.
- Clinical Data Utilization: Tempus AI leverages vast clinical and genomic datasets to drive AI-powered diagnostics and treatment recommendations, and despite its shares declining over 20% year-to-date, ARK's continued buying demonstrates unwavering confidence in its long-term potential.
- Industry Structural Shift: The pharmaceutical sector is expected to face a patent cliff in the next five years, creating opportunities for AI-native platforms to accelerate drug discovery and optimize clinical trials, with emerging players like Totaligent enhancing their biologics-driven data capabilities through strategic acquisitions.
See More
